mebendazole has been researched along with Triple Negative Breast Neoplasms in 7 studies
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mebendazole (MBZ) is a well-known anti-parasite drug with significant anti-cancer properties." | 1.72 | Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment. ( Ghahremani, F; Hosseini, M; Jolfaie, NA; Kefayat, A; Rafienia, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, HS | 2 |
| Ko, YS | 2 |
| Jin, H | 2 |
| Kang, KM | 2 |
| Ha, IB | 2 |
| Jeong, H | 2 |
| Song, HN | 1 |
| Kim, HJ | 2 |
| Jeong, BK | 2 |
| Kefayat, A | 1 |
| Hosseini, M | 1 |
| Ghahremani, F | 1 |
| Jolfaie, NA | 1 |
| Rafienia, M | 1 |
| Zhen, Y | 2 |
| Yuan, Z | 1 |
| Zhang, J | 1 |
| Chen, Y | 1 |
| Fu, Y | 1 |
| Liu, Y | 1 |
| Fu, L | 2 |
| Zhang, L | 3 |
| Zhou, XL | 2 |
| Lee, JH | 1 |
| Joe, NS | 1 |
| Godet, I | 1 |
| Milki, N | 1 |
| Ain, NUI | 1 |
| Oza, HH | 1 |
| Riggins, GJ | 1 |
| Gilkes, DM | 1 |
| Zhao, R | 1 |
| Wang, M | 1 |
| Jiang, X | 1 |
| Gao, F | 1 |
| Bochkur Dratver, M | 2 |
| Yazal, T | 1 |
| Dong, K | 1 |
| Nguyen, A | 1 |
| Yu, G | 1 |
| Dao, A | 1 |
| Duhachek-Muggy, S | 1 |
| Bhat, K | 1 |
| Alli, C | 1 |
| Pajonk, F | 1 |
| Vlashi, E | 1 |
7 other studies available for mebendazole and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line | 2021 |
Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.
Topics: Animals; Chitosan; Folic Acid; Humans; Hydrogen-Ion Concentration; Mebendazole; Mice; Nanoparticles; | 2022 |
Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer.
Topics: Dynamins; Humans; Mebendazole; Mitochondria; Mitophagy; Triple Negative Breast Neoplasms; Ubiquitin- | 2022 |
Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; Killer Cells, Natural; Meb | 2022 |
Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness.
Topics: Cell Line, Tumor; Female; Humans; Integrin beta4; Mebendazole; Triple Negative Breast Neoplasms | 2022 |
Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Repositioning; Female; Hum | 2020 |
Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer.
Topics: Animals; Apoptosis; Cell Dedifferentiation; Cell Line, Tumor; DNA Breaks, Double-Stranded; Female; H | 2019 |